In June 2025, we reported on a study that showed long-term survival with undetectable disease in heavily pretreated multiple myeloma. The results not only added fresh evidence of efficacy for CAR ...

CAR T-cell therapy sequencing shows higher response rates and progression-free survival in BCMA-naive patients, with ciltacabtagene autoleucel outperforming idecabtagene vicleucel. Effective CAR ...

In a phase 1–2 trial, teclistamab, a bispecific antibody targeting CD3 on T-cell surfaces and B-cell maturation antigen on myeloma cells, showed durable responses in heavily pretreated patients with ...

Stage 2 multiple myeloma involves intermediate cancer levels, requiring treatment for symptoms like bone issues, anemia, and kidney problems. Diagnosis includes blood, urine, imaging tests, and ...

Since the beginning of this century, advances in understanding the biology of multiple myeloma have transformed the disease from universally fatal to curable for a substantial proportion of patients.

Histopathological image of multiple myoloma. Smear preparation of bone marrow aspirate stained with May-Grünwald-Giemsa procedure. It doest not represent a histopathologic image but essentially helps ...

As many as one third of newly diagnosed multiple myeloma (MM) cases are classified as high risk, with widely varying rates of progression-free survival (PFS), as shown in a validation of consensus ...

Multiple myeloma is a chronic (long-term) blood cancer that affects plasma cells made in the bone marrow, which is spongy tissue found inside bones. While people with multiple myeloma can live for ...

Multiple myeloma is a form of blood cancer you may never have heard of–and that makes sense, because it’s, thankfully, pretty rare. That said, if you’re one of the unlucky few (your average lifetime ...

Multiple myeloma is a blood cancer affecting plasma cells, causing abnormal antibody production and bone damage. Diagnosis involves blood tests, bone marrow biopsy, imaging, and genetic analysis to ...

Disparities in multiple myeloma outcomes are linked to income and geographic location, with lower-income and rural patients experiencing higher mortality rates. Limited access to insurance, novel ...

The Spanish Society of Hematology and Hemotherapy (SEHH) held its ninth “HematoAvanza” Outreach Conference at the Pazo de San Lorenzo in Santiago, Spain. The event brought together hematologists, ...